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SUMMARY
Although the employment of thiopurine metabolites profiles to decide on allopurinol co-therapy is 
intellectually appealing, their use in determining dosing decisions or use of allopurinol co-therapy 
is based on assumptions which are of unproven clinical importance. If decisions are based on meta-
bolic profiling it is likely to deny many patients the benefits of low dose azathioprine with allopuri-
nol co-therapy (LDAAC). Conversely, the measurement of thiopurine methyl transferase appears 
to be of benefit as it allows tailored dosing which is of particular importance with LDAAC. Poor 
response or side effects to full dose azathioprine (FDA) is common (up to 60%) in inflammatory 
bowel disease (IBD) and results in the need for monoclonals ($15-20,000/patient/year), surgery 
($10,000/patient/surgery), hospitalisations ($7,000/patient/admission) (UK costs) and steroid de-
pendency. With an increasing incidence of IBD in developing nations (surpassing the West) this 
will place a significant strain on these economies. Evidence emerging from centres in the UK, Aus-
tralia and North America indicate an improvement in efficacy of using LDAAC over FDA for IBD. 
These observations include by-passing hepatotoxicity, non-pancreatitis side effects and importantly 
increasing the numbers of patients likely to benefit from FDA. If these observations are confirmed 
LDAAC will result in health improvements for IBD patients and significant cost saving for health 
commissioners and patients. The use of LDAA should similarly benefit patients who require aza-
thioprine for other disorders including hepatology, childhood IBD and dermatology. 
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RESUMO
Coterapia com azatioprina e alopurinol para doença inflamatória 
intestinal: experiências e tribulações
Embora o emprego de perfis de metabólitos tiopurina para decidir sobre o alopurinol coterapia seja 
intelectualmente atraente, seu uso nas decisões de dosagem ou utilização de alopurinol coterapia 
baseia-se em suposições cuja importância clínica não foi comprovada. Se as decisões baseiam-se 
em perfil metabólico é possível que sejam negados a muitos pacientes os benefícios da coterapia 
com baixa dose de azatioprina e alopurinol (CBDAA). Por outro lado, a medição de metiltransfe-
rase tiopurina parece ser benéfica, pois permite a dosagem sob medida, particularmente impor-
tante com CBDAA. É comum a ocorrência de resposta insatisfatória ou de efeitos adversos à dose 
completa de azatioprina (DCA) (mais de 60%) na doença inflamatória intestinal, resultando na 
necessidade de monoclonais ($15-20,000/paciente/ano), de cirurgia ($10,000/pacientes/cirurgia), 
e de internações ($7,000/paciente/admissão) (custos Reino Unido) e na dependência de esteroides. 
O aumento da incidência de DII em países em desenvolvimento (ultrapassando o Ocidente) de-
mandará um esforço ainda maior dessas economias. Novas evidências de centros no Reino Unido, 
na Austrália e nos EUA indicam uma melhoria na eficácia do uso CBDAA e DCA para DII. Essas 
novas considerações incluem a superação da hepatotoxicidade e dos efeitos colaterais da pandreati-
te além de considerável aumento no número de pacientes propensos a beneficiarem-se da DCA. Se 
estas observações forem confirmadas, a CBDAA gerará melhorias na saúde para pacientes  com DII 
e economia significativa de custos para os orgãos de saúde e para os pacientes. O uso de CBDAA 
deve beneficiar também os pacientes que necessitam de azatioprina para outros distúrbios, incluin-
do hepatologia, DII infantil e dermatologia. 
Unitermos: Azatioprina; mercaptopurina; alopurinol; doença inflamatória intestinal; doença de 
Crohn.
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INTRODUCTION
Inflammatory bowel disease (IBD; comprising Crohn’s 
disease and ulcerative colitis) is a chronic relapsing life-
long disorder of unknown aetiology, affecting the gastro-
intestinal tract. IBD is more common in Northern Europe 
and developed nations, although the numbers of sufferers 
in developing nations may well exceed that in the West1,2. 
IBD has a spectrum of disease severity which mainly de-
termines its treatment and long-term natural history. 
Crohn’s disease (CD) often progresses to non-curative 
surgery (50% in 10 years, 80% in a lifetime), and the use 
of immunosuppressives is steadily increasing (up to 70%) 
to meet this challenge3. In Northern Europe and the USA, 
rates of surgery for ulcerative colitis (UC) in the past two 
decades have decreased from over 30% to 5-11%. During 
that time there has been an increase in the intake of immu-
nosuppressive or biological agents, from about 3% from 
1960-1979 to 20% for the period 1980-20014.
The thiopurine drugs 6-mercaptopurine (6MP) and 
its pro-drug azathioprine (AZA), have well known long-
term safety profiles and are often used as first-line im-
munosuppressives in IBD. There have been conflicting 
reports about the impact of thiopurines on the natural 
history of CD3,5,6. However, several encouraging reports 
have recently emerged. A Cardiff cohort demonstrated 
a significant reduction in surgery and steroid use since 
thiopurines have been more extensively used in CD5. Fall-
ing rates of surgery following earlier and more aggressive 
use of AZA/6MP have also been reported for a paediatric 
population6 and a large cohort from Copenhagen7. As IBD 
most commonly affects patients during their reproductive 
years the long-term safety of thiopurines in pregnancy has 
been a therapeutic advantage. Failure to respond to thio-
purine can have significant consequences for a patient. For 
CD, failure to respond to thiopurines frequently leads to 
the use of expensive ‘biological’ therapy (monoclonal anti-
body drugs) – if affordable for the patient – in preference 
to other immunosuppressants such as methotrexate partly 
due to the teratogenicity. However for UC, thiopurine fail-
ure leads to a colectomy in up to 88% of cases8. 
Adverse drug reactions (ADRs) to thiopurines result 
in stopping treatment and loss of the possibility of gain-
ing the benefits from a thiopurine response, while not-
ing that gastric ADRs to AZA/6MP maybe exacerbated 
by IBD disease factors9. However, it is likely that the fre-
quency of side effects to these thiopurines are far higher 
than previously determined by retrospective studies10,11 
that reported thiopurine ADRs in approx. 15% of patients, 
with a recent prospective study suggesting an ADR rate up 
to 40%12. The commonest ADR is gastrointestinal intoler-
ance (especially nausea); others are much less common 
include flu-like symptoms, hepatotoxicity, rash, pancreati-
tis and myelotoxicity. Some of these side effects can have 
a dose-dependant element, e.g. hepatotoxicity occurs in 
25-30% of patients who receive supra-therapeutic doses 
of AZA of >  2  mg/kg13. Gastric intolerance, myelotoxic-
ity and flu-like symptoms can occur both as the dose of 
AZA/6MP is slowly bought to therapeutic levels or when 
increased to supra-therapeutic levels when pursuing a 
positive response. Pancreatitis and rash appears to have 
an idiosyncratic or allergic quality and may reoccur on re-
exposure to AZA/6MP. 
Several studies have evaluated the impact of mod-
ern use of immunosuppressives including thiopurines. 
A study by Cosnes et al.3 did not find any reduction in 
surgical rates between 1978-2002 for patients receiving 
thiopurines, but the half of the group that would have 
been predicted to have a lower rate of surgery started the 
AZA/6MP less than three months before surgery, and 
AZA/6MP takes at least 12 weeks to work, i.e. surgery was 
undertaken among the patient cohort too soon for them 
to benefit from thiopurines. In contrast, a large Cardiff 
cohort in which AZA/6MP was started earlier had signifi-
cantly reduced surgical rates5.
Failure to respond or adverse reactions to thiopurines 
can have a high cost. Patients who cannot take AZA/6MP 
have a high probability of hospitalisations, surgery, nutri-
tional therapies, monoclonal therapies and occasionally 
parenteral nutrition. A hospital bed in the UK in 2011 costs 
£  600-800/patient/day, while monoclonal therapies 
costs range from £ 10.000-15.000/patient/year: these thera-
pies are thus expensive but far cheaper than hospitalisation. 
However, monoclonals suffer from significant loss of re-
sponse each year of treatment, limiting their long-term use.
The genetics of thiopurine response are concerned 
with the activation and inactivation of the parent drugs 
(Figure 1). Genetic polymorphism of thiopurine methyl-
transferase (TPMT) can produce raised levels of the cyto-
toxic and immunosuppressive metabolites of AZA/6MP, 
the thioguanine nucleotides (TGNs), accompanied by low 
levels of methylated-6MP (6MeMP); this has been well-
documented as producing myelotoxicity. However, the 
therapeutic value of erythrocyte TGN levels in predicting a 
positive response to AZA/6MP has yet to be confirmed with 
prospective studies: the value of TGN levels in erythrocytes 
is limited as they do not reflect levels in the target cells, the 
T-lymphocytes14. The cytotoxicity of TGNs has always been 
assumed to be concentrated on the bone marrow, however a 
prospective study has shown that nausea is also a common 
early adverse reaction accompanying low TPMT activity 
and raised TGNs12. Polymorphic deficiency of the inosine 
triphosphate pyrophosphohydrolase (ITPA) gene, which 
is associated with accumulation of an unusual thiopurine 
metabolite thio-ITP was initially reported as associated with 
flu-like symptoms12, but this gene has also been linked to 
other thiopurine-induced adverse events in IBD patients15.
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The association of hepatotoxicity with thiopurines is 
well established. Although 6MP is thought to be less hepa-
totoxic than AZA16, no difference in hepatotoxicity rates 
was found between the two drugs in a meta-review17. In 
addition, a prospective evaluation found the rate of hepa-
totoxicity in IBD was high (13% abnormal liver function, 
10% hepatotoxicity)18, suggesting under-reporting in ret-
rospective studies.
The concept of hepatotoxicity related to high methyl-
ated thiopurines (and thus high TPMT) has been around 
since 1967 when 6MeMP was tested as a therapy for leu-
kaemia19, and others have since provided evidence for 
this association20,21. However, similar to TGNs, measure-
ment of erythrocyte 6MeMP may be limiting in its clini-
cal application, due to two factors. First, most assays do 
not distinguish between inert 6MeMP and metabolically 
active 6-thio-IMP. Second, erythrocyte levels of 6MeMP 
have been demonstrated to be quite different to leucocytes 
(i.e. the target cells) and presumably other ‘by-stander’ 
cells such as hepatocytes. As a result, erythrocytes may be 
poor markers of hepatotoxicity: 90% of patients with high 
6MeMP have no hepatotoxicity and conversely 40% of pa-
tients with hepatotoxicity have low 6MeMP18.
Other genetic factors affecting thiopurine response 
may emerge. Xanthine oxidase effects have been stud-
ied and appear to have little correlation with response, 
although its role is far from clear22. Aldehyde oxidase 
polymorphism may be related to some side effects of AZA 
and requires further study23 as does IMP dehydrogenase24. 
For the present, the usefulness of erythrocyte metabolite 
levels as a guide to thiopurine treatment has been shown 
to be limited25, and other parameters (clinical response, 
CRP, ESR, leucocyte count and liver function tests) remain 
more reliable for routine monitoring.
TRIBULATIONS: ALLOPURINOL CO-THERAPY FOR  
THIOPURINES 
Allopurinol has a short half-life (2-3 hrs) and is weak com-
pletive inhibitor of xanthine oxidase (XO).  Oxypurinol is 
generated by the action of aldehyde oxidase and XO on al-
lopurinol, resulting in a longer-lived (18-30 hrs) metabolite 
that has a more potent non-completive inhibition of XO. In-
terestingly, allopurinol was originally designed as a XO in-
hibitor to improve bioavailability and the therapeutic index 
of 6MP26. Studies confirmed a 3-4x improvement in 6MP 
bioavailability, but there was a lack of improvement in the 
therapeutic index for leukemia. Subsequently, allopurinol’s 
effect on lowering uric acid levels in patients receiving cyto-
toxic therapy lead to its more famous role in treating gout. 
The synergistic effect of allopurinol on thiopurine 
therapy was recognised early in the development of renal 
transplantation as based on the bioavailability studies of 
Figure 1 – Metabolic activation and targets of thiopurines. TPMT, thiopurine methyl-transferase; AO, aldehyde oxidase; XO, 
xanthine oxidase; HGPRT, hypoxanthine guanine phosphoribosyl-transferase; ITPase, inosine triphosphate pyrophospho-
hydrolase; IMPDH, inosine monophosphate dehydrogenase; 6MP, 6-mercaptopurine; 6MeMP, methyl-6MP; 8-OH-6MeMP, 
8-hydroxy-6MeMP; 6TU, 6-thiouric acid.
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Elion26 – kidney transplant patients receiving allopurinol 
for gout were determined to require an AZA dose of only 
one-third normal until the oxypurinol was eliminated27. 
However, the strong synergism of allopurinol with thio-
purines paradoxically led to it being contra-indicated in 
pharmaceutical practice, with numerous reports of toxic-
ity or death arising from inadvertent thiopurine/allopuri-
nol co-prescription. As a result, deliberate co-therapy was 
not considered. 
Co-therapy of allopurinol with azathioprine was first 
revived by Chocair in 199328, who reported a significantly 
higher graft survival among renal transplants. A similar 
improvement in heart graft survival was found by Chrza-
nowska and Krzymański29 who were first to link allopu-
rinol effects to changes in patterns of AZA metabolites, 
noting that for a given AZA dose erythrocyte TGN levels 
were greatly increased while 6MeMP levels were lowered. 
This contradicted the generally accepted mechanism for 
allopurinol interaction with thiopurines, which had previ-
ously been attributed to XO inhibition, despite the fact that 
XO has little affinity for 6MP30, particularly at low doses22. 
The thiopurine metabolite effects of allopurinol imply in-
hibition of TPMT, but work done by Sparrow et al. could 
not find direct inhibition of TPMT in patients receiving 
allopurinol31. Recently, Marinaki et al. have reported that 
thioxanthine, which accumulates during allopurinol ther-
apy, inhibits TPMT: whether this explains the mechanism 
requires further investigation32.
Sparrow et al. were the first to report the deliberate use 
of thiopurine/allopurinol co-therapy for IBD patients who 
were showing poor thiopurine response accompanied by a 
specific metabolic profile (high 6MeMP and low TGN)33. 
A significant positive response was demonstrated in this 
sub-set of patients, with clinical improvement in almost 
70% of those treated with reduced dose AZA/6MP plus 
allopurinol. Sparrow has further developed the concept of 
preferential methylation as a basis for justifying allopurinol 
co-therapy31,34, and this has been supported by others35,36. 
The concept linking lack of response to excessive meth-
ylation was also supported by our prospective study that 
showed genetically wild-type TPMT patients who toler-
ated 2mg/kg AZA but had very high erythrocyte activity 
were at risk of poor outcome (43% response) compared 
with patients with normal TPMT activity (81% response)12, 
echoing an earlier retrospective study37, but others have 
pointed out that the positive predictive value of thiopurine 
metabolite ratios is poor18.
AN OPEN-LABELLED TRIAL: AZATHIOPRINE-ALLOPURINOL 
CO-THERAPY
To examine the outcome of using allopurinol co-therapy in 
IBD patients with poor response and without prior metab-
olite monitoring, an open-labelled trial was performed38. 
Clinical and blood monitoring was standard as used for 
thiopurine monotherapy. Patients were given 100mg al-
lopurinol in combination with an AZA dose that was ap-
proximately a third of a TPMT-corrected dose of 2mg/kg 
(wild-type) or 1mg/kg (partial TPMT deficiency), i.e. 
0.7 mg/kg for TPMT wild-type and 0.35mg/kg AZA for 
partial deficiency. 
Of the 25 patients treated, an unusually high propor-
tion (73%) had a full clinical response. During an 18-month 
evaluation period, 4 patients had reversible side effects: 2 
episodes of myelotoxicity were detected and both respond-
ed to a simple reduction of AZA dose, while 2 patients had 
myalgia which responded to reduction of allopurinol dose 
(from 100 to 50mg) without loss of clinical response. 
LONG-TERM ALLOPURINOL CO-THERAPY WITH THIOPURINES
Our first long-term treatment with AZA/allopurinol was 
reported for a patient who had been on co-therapy for 5 
years22. Initially, we restricted co-therapy to patients who 
had experienced hepatotoxicity on AZA or 6MP following 
dose escalation, with excellent long-term results38. Howev-
er, since 2000 we have expanded the use of allopurinol co-
therapy beyond overcoming hepatotoxicity, to unselected 
non-responders, and the clinical response has ranged be-
tween 70-80%39,40, similar to that recorded in this open-
label trial and approximately double the usual long-term 
success rate observed with AZA or 6MP alone. 
METABOLITE PROFILING SELECTION
Sparrow et al.31,33 were first to demonstrate that with thio-
purine-allopurinol co-therapy a positive response was 
achievable in over 70% of IBD patients who previously had 
poor response accompanied by hepatoxicity upon dose es-
calation, identified as a subset of patients exhibiting prefer-
ential erythrocyte methylation (high 6MeMP levels and low 
TGN). This was similar to Chrzanowska and Krzyman-
ski29, who showed that co-prescription of allopurinol sig-
nificantly increased erythrocyte TGN levels and reduced 
6MeMP in heart transplant patients receiving AZA immu-
nosuppression. 
The strategy developed by Sparrow relies on at least two 
assumptions: 1) erythrocyte TGNs are predictive of clinical 
response, and 2) high erythrocyte 6MeMP levels predict a 
diversion of metabolism away from activation to TGN. As 
a result, restricting allopurinol use to erythrocyte metabolic 
profiles identified as ‘high methylators’ (or ‘shunters’) has led 
inadvertently to allopurinol co-therapy being recommend-
ed only for non-responders with a specific metabolic pro-
file41. This approach also suffers from at least two additional 
restrictions: 1) the proportion of patients not responding to 
AZA/6MP who fit this profile is not known, and 2) the facil-
ity to measure metabolites to identify this subset of patients 
is restricted to a few developed nations. 
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CONCLUSIONS
The more universal use of co-therapy – as advocated here 
– thus increases the number of patients eligible for allo-
purinol, especially as they do not require prior metabolic 
profiling. In addition, direct co-therapy bypasses the 
lengthy (minimum 3 months) waiting period required 
for a positive response to classical thiopurine therapy 
that can add to the significant morbidly and suffering as-
sociated with symptoms from active and severe inflam-
matory bowel disease. 
Potential patients can therefore be divided into:
A. Prior thiopurine exposure: This includes patients 
who have hepatotoxicity38 non-pancreatic adverse 
drug reactions39 or poor thiopurine response with-
out prior metabolite profiling/monitoring40.
B. Thiopurine naive: IBD patients in this group in-
clude those exhausted with frequent flares and/
or other disease activity, and prefer to avoid any 
chance of early reactions or poor response41. 
Ulcerative colitis patients with high risk of colecto-
my, including colitics exhausted with poor response 
to steroids and 5ASA’s, and those with acute severe 
disease acute requiring infliximab/cyclosporine.
There are two constraints to co-therapy. First, it is rea-
sonable to consider the predictive value of TPMT activ-
ity/genotype, and calculate an appropriately lowered dose 
(50% normal dose for TPMT carriers), then the dose is 
reduced to one third of the lower dose when allopurinol 
is included. Second, there will be a small proportion of pa-
tients who are hypersensitive or intolerant of allopurinol: 
this is relatively rare in European populations but is a sig-
nificant among Han Chinese42. 
Interestingly, hepatotoxicity and neutropenia have 
been by-passed with allopurinol co-therapy in patients 
who are TPMT heterozygotes, and this suggests that al-
lopurinol co-therapy may reduce toxicity in other ways 
in addition to lowering high 6MeMP, perhaps through a 
simple dose-lowering mechanism. 
In conclusion, it is important to note that while thio-
purines offer a cheap, safe and long-term treatment option 
for IBD, they suffer from significant rate of poor response 
and side effects. In particular, poor responders prescribed 
a higher dose of AZA from the beginning of therapy or are 
dose escalated, have 25-30% chance of developing hepato-
toxicity, with an uncertain clinical outcome.  Alternatively, 
low dose AZA/6MP with allopurinol co-therapy is poten-
tially be less toxic and can achieve at least 70% clinical re-
sponse among poor responders. 
But co-therapy does not need to be restricted to a poor 
responder subset: it can be used from the initiation of ther-
apy for most patients who are to be treated with thiopu-
rines. Allopurinol co-therapy offers the hope of reducing 
side effects and improving clinical efficacy of thiopurines 
without any significant risk or cost. If this promise is borne 
out then there will be an improvement in patient experi-
ence with IBD and commissioning for health care costs. 
As allopurinol co-therapy appears to significantly lower 
the chance of side effects and increases the probability of 
a positive response, this may also significantly reduce pa-
tients’ therapeutic uncertainties and improve their experi-
ence of thiopurines. 
ACKNOWLEDGMENTS
This paper was presented in part to the III International 
Thiopurine Symposium, held at the Instituto de Educação 
e Ciências, Hospital Alemão Oswaldo Cruz, São Paulo, 
September 30th – October 2nd, 2010. 
REFERENCES
1. Economou M, Pappas G. New global map of Crohn’s disease: Genet-
ic, environmental, and socioeconomic correlations. Inflamm Bowel 
Dis. 2008;14:709-720.
2. Benchimol EI, Kyle J. Epidemiology of pediatric inflammatory bowel 
disease: A systematic review of international trends. Inflamm Bowel 
Dis. 2011;17:423-439.
3. Cosnes J, Nion-Larmurier I, Beaugerie L, Afchain P, Tiret E, Gendre 
JP. Impact of the increasing use of immunosuppressants in Crohn’s 
disease on the need for intestinal surgery. Gut. 2005;54:237-241.
4. Magro F, Rodrigues A, Vieira AI, Portela F, Cremers I, Cotter J, et al. 
Review of the disease course among adult ulcerative colitis population-
based longitudinal cohorts. Inflamm Bowel Dis. 2012;18(3):573-83.
5. Ramadas AV, Gunesh S, Thomas GA, Williams GT, Hawthorne AB. 
Natural history of Crohn’s disease in a population-based cohort from 
Cardiff (1986-2003): a study of changes in medical treatment and 
surgical resection rates. Gut. 2010;59:1200-1206.
6. Markowitz J, Grancher K, Kohn N, Lesser M, Daum F. A multicenter 
trial of 6-mercaptopurine and prednisone in children with newly di-
agnosed Crohn’s disease. Gastroenterology. 2000;119:895-902.
7. Jess T, Riis L, Vind I, Winther KV, Borg S, Binder V, et al. Changes in 
clinical characteristics, course, and prognosis of inflammatory bowel 
disease during the last 5 decades: a population-based study from Co-
penhagen, Denmark. Inflamm Bowel Dis. 2007;13:481-489.
8. Moskovitz DN, Van Assche G, Maenhout B, Arts J, Ferrante M, 
Vermeire S, et al. Incidence of colectomy during long-term follow-
up after cyclosporine-induced remission of severe ulcerative colitis. 
Clin Gastroenterol Hepatol. 2006;4:760–765.
9. Weersma RK, Peters FT, Oostenbrug LE, van den Berg AP, 
van Haastert M, Ploeg RJ, et al. Increased incidence of azathio-
prine-induced pancreatitis in Crohn’s disease compared with other 
diseases. Aliment Pharmacol Ther. 2004;20:843-850.
10. Present DH, Meltzer SJ, Krumholz MP, Wolke A, Korelitz BI. 6-Mer-
captopurine in the management of inflammatory bowel disease: 
short- and long-term toxicity. Ann Intern Med. 1989;111:641-649.
11. Sandborn W, Sutherland L, Pearson D, May G, Modigliani R, Prantera 
C. Azathioprine or 6-mercaptopurine for inducing remission of 
Crohn’s disease. Cochrane Database Syst Rev. 2000;(2):CD000545.
12. Ansari A,  Arenas M, Greenfield S, Morris D, Lindsay J, Smith M, et 
al. Prospective evaluation of the pharmacogenetics of azathioprine 
in the treatment of inflammatory bowel disease. Aliment Pharmacol 
Ther. 2008;28:973-983.
13. Dubinsky MC, Yang H, Hassard PV, Seidman EG, Kam LY, Abreu 
MT, et al. 6-MP metabolite profiles provide a biochemical explana-
tion for 6-MP resistance in patients with inflammatory bowel dis-
ease. Gastroenterology. 2002;122:904-915.
14. Duley JA, Florin THJ. Thiopurine therapies: problems, complexities, 
and progress with monitoring thioguanine nucleotides. Ther Drug 
Monit. 2005;27:647-654.
AZATHIOPRINE CO-THERAPY WITH ALLOPURINOL FOR INFLAMMATORY BOWEL DISEASE: TRIALS AND TRIBULATIONS
33Rev Assoc Med Bras 2012; 58(Suppl 1):S28-33
15. von Ahsen N, Armstrong VW, Behrens C, von Tirpitz C, Stallmach 
A, Herfarth H, et al. Association of inosine triphosphatase 94C>A 
and thiopurine S-methyltransferase deficiency with adverse events 
and study drop-Outs under azathioprine therapy in a prospective 
Crohn Disease study. Clin Chem. 2005;51:2282-8.
16. McGovern DPB, Travis SPL, Duley JA, Shobowale-Bakre M, 
Dalton HR. Azathioprine intolerance in patients with IBD may 
be imidazole-related and is independent of TPMT activity. 
Gastroenterology. 2002;122:838-839. 
17. Bastida G, Nos P, Aguas M, Beltrán B, Rubín A, Dasí F, et al. 
Incidence, risk factors and clinical course of thiopurine-induced 
liver injury in patients with inflammatory bowel disease. Aliment 
Pharmacol Ther. 2005;22:775-782.
18. Shaye OA, Yadegari M, Abreu MT, Poordad F, Simon K, 
Martin P, et al. Hepatotoxicity of 6-mercaptopurine (6-MP) and 
azathioprine (AZA) in adult IBD patients. Am J Gastroenterol. 
2007;102:2488-2494.
19. Luce JVT, Frenkel E, Isassi A. Clinical studies of 6-methylmer-
captopurine riboside (NSC-40774) in acute leukemia. Cancer 
Chemother Rep. 1967;51:535-546.
20. Cuffari C, Théorêt Y, Latour S, Seidman G. 6-Mercaptopurine me-
tabolism in Crohn’s disease: correlation with efficacy and toxicity. 
Gut. 1996;39:401-406.
21. Dubinsky MC, Lamothe S, Yang HY, Targan SR, Sinnett D, 
Théorêt Y, et al. Pharmacogenomics and metabolite measurement 
for 6-mercaptopurine therapy in inflammatory bowel disease. 
Gastroenterology. 2000;118:705-713.
22. Ansari A, Aslam Z, De Sica A, Smith M, Gilshenan K, Fairbanks L, 
et al. The influence of xanthine oxidase on thiopurine metabolism 
in Crohn’s disease. Aliment Pharmacol Ther. 2008;28:749-57. 
23. Smith MA, Marinaki AM, Arenas M, Shobowale-Bakre M, Lewis 
CM, Ansari A, et al. Novel pharmacogenetic markers for treatment 
outcome in azathioprine-treated inflammatory bowel disease. 
Aliment Pharmacol Ther. 2009;30:375-384.
24. Haglund S, Vikingsson S, Söderman J, Hindorf U, Grännö C, 
Danelius M, et al. The role of inosine-5’-monophosphate dehydro-
genase in thiopurine metabolism in patients with inflammatory 
bowel disease. Ther Drug Monit. 2011;33:200-208.
25. Haglund S, Taipalensuu J, Peterson C, Almer S. IMPDH activity 
in thiopurine-treated patients with inflammatory bowel disease – 
relation to TPMT activity and metabolite concentrations. Br J Clin 
Pharmacol. 2008;65:69-77.
26. Elion GB. Nobel lecture in physiology or medicine –1988. The pu-
rine path to chemotherapy. In Vitro Cell Dev Biol. 1989;25:321-330.
27. EBPG Expert Group on Renal Transplantation. European Best 
Practice Guidelines for Renal Transplantation: Section IV. Long-
term management of the transplant recipient. Nephrol Dial 
Transplant. 2002;17:1-67.
28. Chocair P, Duley J, Simmonds HA, Cameron JS, Ianhez L, Arap S, et 
al. Low-dose allopurinol plus azathioprine/ cyclosporin/ predniso-
lone, a novel immunosuppressive regimen. Lancet. 1993;342:83-84. 
29. Chrzanowska M, Krzymański M. Determination of 6-thioguanine 
and 6-methylmercaptopurine metabolites in renal transplantation 
recipients and patients with glomerulonephritis treated with aza-
thioprine. Ther Drug Monit.  1999;21:231-237. 
30. Krenitsky TA, Tuttle JV, Cattau EL Jr, Wang P. A comparison of 
the specificities of xanthine oxidase and aldehyde oxidase. Arch 
Biochem Biophys. 1972;150:585-599.
31. Sparrow MP, Hande SA, Friedman S, Cao D, Hanauer SB. Effect 
of allopurinol on clinical outcomes in inflammatory bowel dis-
ease nonresponders to azathioprine or 6-mercaptopurine. Clin 
Gastroenterol Hepatol. 2007;5:209-214.
32. Blaker PA, Arenas M, Fairbanks L, Irving P, Marinaki AM, 
Sanderson J. A biochemical mechanism for the role of allopurinol 
in TPMT inhibition. Gut. 2011;60:A132-A133.
33. Sparrow MP, Hande SA, Friedman S, Lim WC, Reddy SI, Cao D, 
et al. Allopurinol safely and effectively optimizes tioguanine me-
tabolites in inflammatory bowel disease patients not responding 
to azathioprine and mercaptopurine. Aliment Pharmacol Ther. 
2005;22:441-446.
34. Leung Y, Sparrow MP, Schwartz M, Hanauer SB. Long term effi-
cacy and safety of allopurinol and azathioprine or 6-mercaptopu-
rine in patients with inflammatory bowel disease. J Crohns Colitis. 
2009;3:162-167.
35. Gardiner SJ, Gearry RB, Burt MJ, Chalmers-Watson T, Chapman 
BA, Ross AG, et al. Allopurinol might improve response to azathio-
prine and 6-mercaptopurine by correcting an unfavorable metabo-
lite ratio. Pharmacogenet Genomics. 2011;15:365-369. 
36. Rahhal RM, Bishop WP. Initial clinical experience with allopuri-
nol-thiopurine combination therapy in pediatric inflammatory 
bowel disease. Inflamm Bowel Dis. 2008;14:1678-82.
37. Ansari A, Hassan C, Duley J, Marinaki A, Shobowale-Bakre EM, 
Seed P, et al. Thiopurine methyltransferase activity and the use of 
azathioprine in inflammatory bowel disease. Aliment Pharmacol 
Ther. 2002;16:1743-1750.
38. Ansari A, Elliott T, Baburajan B, Mayhead P, O’Donohue J, Chocair 
P, et al. Long term outcome of using allopurinol co-therapy as a strat-
egy for overcoming thiopurine hepatotoxicity in treating inflamma-
tory bowel disease. Aliment Pharmacol Ther. 2008;28:734-41.
39. Ansari A, Patel N, Sanderson J, O’Donohue J, Duley JA, Florin 
TH. Low-dose azathioprine or mercaptopurine in combination 
with allopurinol can bypass many adverse drug reactions in pa-
tients with inflammatory bowel disease. Aliment Pharmacol Ther. 
2010;31:640-647.  
40. Stamoulos P, Ansari A, Stenner J, Mackenzie G, McSorley H. Aza-
thioprine/allopurinol co-therapy is an effective treatment for pa-
tients with inflammatory bowel disease who exhibit no response 
or side-effects to thiopurines without the need for metabolite level 
measurements. Gut. 2011;60:A218-A219.
41. Gardiner SJ, Gearry RB, Burt MJ, Chalmers-Watson T, Chapman 
BA, Ross AG, et al. Allopurinol might improve response to azathio-
prine and 6-mercaptopurine by correcting an unfavorable metabo-
lite ratio. J Gastroenterol Hepatol. 2011;26:49-54.
42. Hung SI, Chung WH, Liou LB, Chu CC, Lin M, Huang HP, et al. 
HLA-B*5801 allele as a genetic marker for severe cutaneous ad-
verse reactions caused by allopurinol. Proc Natl Acad Sci USA. 
2005;102:4134-4139.
